Horizon Therapeutics PLC (NASDAQ:HZNP)
| 62.99 Delayed Data As of Sep 23 |  +0.36 / +0.57%Today’s Change | 57.84 Today|||52-Week Range 120.54 | -41.55% Year-to-Date |
Latest HZNP News | Press Releases
| Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal Sep 13 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 62.63 |
| Today’s open | 62.42 |
| Day’s range | 61.33 - 63.05 |
| Volume | 259,513 |
| Average volume (3 months) | 2,510,204 |
| Market cap | $14.7B |
Data as of 4:00pm ET, 09/23/2022
Growth & Valuation
| Earnings growth (last year) | +24.00% |
| Earnings growth (this year) | -0.95% |
| Earnings growth (next 5 years) | +11.00% |
| Revenue growth (last year) | +46.63% |
| P/E ratio | 19.4 |
| Price/Sales | 7.87 |
| Price/Book | 3.10 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| INCYIncyte Corp | -0.49 | -0.73% |
| CTLTCatalent Inc | -3.03 | -3.83% |
| ---- | ||
| BHVNBiohaven Pharmaceuti... | +0.59 | +0.39% |
Data as of 4:00pm ET, 09/23/2022
Financials
| Next reporting date | November 7, 2022 |
| EPS forecast (this quarter) | $1.07 |
| Annual revenue (last year) | $3.2B |
| Annual profit (last year) | $534.5M |
| Net profit margin | 16.57% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Dublin, Dublin |
Forecasts
